Efficacy of a Spatial Repellent for Control of *Aedes*-Borne Virus Transmission: A Cluster Randomized Trial in Iquitos, Peru

Amy C. Morrison, Ph.D.[1,2+], Robert C. Reiner Jr., Ph.D.[3+], William H. Elson, M.B.B.S.[4], Helvio Astete, M.S.[2], Carolina Guevara, M.S.[2], Clara del Aguila, B.S.[5], Isabel Bazan, M.D.[2], Crystyan Siles, M.D.[2], Patricia Barrera, M.S.[2], Anna B. Kawiecki, M.S.[1], Christopher M. Barker, Ph.D.[1], Gissella M. Vasquez, Ph.D.[6], Karin Escobedo-Vargas, B.S.[6], Carmen Flores-Mendoza, Ph.D.[6], Alfredo A. Huaman, B.S.[2], Mariana Leguia, Ph.D.[7], Maria E. Silva, Ph.D.,[2] Sarah A. Jenkins, Ph.D.[2], Wesley R. Campbell, M.D.[2], Eugenio J. Abente, Ph.D.[2], Robert D. Hontz, Ph.D.[2], Valerie A. Paz-Soldan, Ph.D.[8], John P. Grieco, Ph.D.[9], Neil F. Lobo, Ph.D.[9+], Thomas W. Scott, Ph.D.[4+], and Nicole L. Achee, Ph.D.[9+*]

[1] Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, California, USA

[2] Department of Virology and Emerging Infectious Diseases, U.S. Naval Medical Research Unit No. 6, Lima, Peru

[3] Department of Health Metrics Sciences, University of Washington, Seattle, Washington, USA

[4] Department of Entomology and Nematology, University of California, Davis, California, USA

[5] Dirección General de Saneamiento Ambiental (DIGESA), Calle Alzamora 410, Iquitos, Peru

[6] Department of Entomology, U.S. Naval Medical Research Unit No. 6, Lima, Peru

[7] Genomics Laboratory, Pontificia Universidad Católica del Perú, Av. Universitaria 1801, San Miguel, Lima, Peru

[8] Department of Global Community Health and Behavioral Sciences, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA

[9] Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, 239 Galvin Life Sciences Center. Notre Dame, Indiana, USA

[+]Indicates equal seniority

*Corresponding author:

Nicole L. Achee, PhD

Research Professor

Eck Institute for Global Health

Department of Biological Sciences

239 Galvin Life Science Center

Notre Dame, Indiana 46556

Ph: 574.631.1561

Email: nachee@nd.edu

ABSTRACT

Background: Over half the world's population is at risk for viruses transmitted by *Aedes* mosquitoes, such as, dengue and Zika. The primary vector, *Aedes aegypti*, thrives in urban environments. Despite decades of effort, cases and the geographic range of *Aedes*-borne viruses (ABV) continue to expand. Rigorously proven vector control interventions that measure protective efficacy against ABV diseases is limited to *Wolbachia* in a single trial in Indonesia, and do not include any chemical intervention. Spatial repellents, a new option for efficient deployment, are designed to decrease human exposure to ABV by releasing active ingredients into the air that disrupt mosquito-human contact.

Methods: A parallel, cluster-randomized controlled trial was conducted in Iquitos, Peru to quantify the impact of a transfluthrin-based spatial repellent on human ABV infection. From 2,907 households across 26 clusters (13 per arm), 1,578 participants were assessed for seroconversion (primary endpoint) by survival analysis. Incidence of acute disease was calculated among 16,683 participants (secondary endpoint). Bi-monthly adult mosquito collections were conducted to compare *Ae. aegypti* abundance, blood-fed capture rate and parity status through mixed effect difference-in-difference analyses. This trial is registered with ClinicalTrials.gov, number NCT03553277.

Findings: The spatial repellent significantly reduced ABV infection by 34·1% (95% CI 6·9%, ∞); p = 0·0236, z=1·98). *Aedes aegypti* abundance and blood-fed capture

rates were significantly reduced by 28·6% (95% CI 24·1%, ∞); z=-9·11) and 12·4% (95% CI 4·2%, ∞); z=-2·43), respectively.

Interpretations: Our trial provides the first conclusive evidence of significant protective efficacy by any chemical vector control intervention, in this case a spatial repellent, to reduce the risk of ABV transmission. Results support vector control as a beneficial component to ABV disease prevention.

Funding: Bill & Melinda Gates Foundation, Military Infectious Disease Program (MIDRP), Defense Threat Reduction Agency (DTRA), and US National Institutes of Health.

Introduction

Aedes-borne viral diseases (ABVD) [e.g., dengue (DENV), chikungunya (CHIKV), Zika (ZIKV), and yellow fever (YF)] are devastating, expanding global public health threats that disproportionally affect low- and middle-income countries. Currently, the primary means for ABVD prevention is controlling the primary mosquito vector*, Aedes aegypti*. Existing vector control interventions, however, have failed to prevent ABV transmission and epidemics. Dengue alone, one of the most rapidly increasing vector-borne infectious diseases,[1,2] with four billion people at risk of infection annually,[3] results in ~400 million infections each year.[2]

There is an urgent need to develop evidence-based guidance for the use of new and existing ABV vector control tools. The evidence-base for vector control against ABVs is weak, despite considerable government investments in WHO-recommended control of larval habitats (larviciding, container removal) and ultra-low volume (ULV) insecticide spraying.[4–8] These strategies continue to be implemented despite the lack of rigorously generated data from controlled clinical trials demonstrating they reduce ABV infection and disease.[9] The only ABV intervention with a proven epidemiological impact in a cluster randomized control trial (cRCT) assessed community mobilization to reduce mosquito larval habitats.[10] A recent test-negative trial with *Wolbachia*-infected mosquitoes reported a significant reduction of dengue illness in Indonesia.[11]

Spatial repellents (SR) are devices that contain volatile active ingredients that disperse in air. The active ingredients can repel mosquitoes from entering a treated

101 space, inhibit attraction to human host cues or disrupt mosquito biting and blood
102 feeding behavior, and, thus, interfere with mosquito-human contact.[12–14] Any of these
103 outcomes reduce the probability of pathogen transmission. Pyrethroid-based spatial
104 repellents have shown efficacy in reducing malaria infections in China[15] and
105 Indonesia.[16] There have, however, been no clinical trials evaluating the protective
106 efficacy of spatial repellents against ABV infection or disease.
107
108 To generate evidence for public health consideration we conducted a parallel, cluster-
109 randomized controlled trial (cRCT) to quantify the epidemiological impact of a
110 transfluthrin-based spatial repellent against ABV transmission in Iquitos, Peru.
111

112 Methods

113 The trial is registered at clinicaltrials.gov (NCT03553277).
114

115 ETHICAL STATEMENT

116 Our study protocol (#NAMRU6.2014.0021, Supplementary Information (SI)) was
117 approved by the U.S. Naval Medical Research Unit No. 6 (NAMRU-6) Institutional
118 Review Board (IRB), which includes Peruvian representation and complies with US
119 Federal and Peruvian regulations governing the protections of human subjects, and
120 the Regional Health Authority (DIRESA), the local branch of the Peruvian Ministry of
121 Health. IRB authorization agreements were established between the NAMRU-6, the
122 University of Notre Dame (Sponsor), the University of California at Davis, and the
123 University of Washington.

TRIAL DESIGN

Detailed study methods are provided in the SI.

Our trial was conducted from June 2015 through March 2019 in the Iquitos and Punchana Districts of Iquitos, Peru (Figure 1, SI Section 1.1). Clusters were selected in January 2015. Enrollment began June 2015. Participation included: 1) a house census, 2) disease surveillance, 3) annual blood draws, 4) bi-monthly entomological surveys, and 5) intervention application in the house. Epidemiological monitoring and entomological surveillance lasted from February 2016 through March 2019 (Figure 2).

Our main objective was to demonstrate and quantify the protective efficacy (PE) of a SR in reducing ABV infection incidence in a human cohort. Qualifying participants were individuals in a participating house who were seronegative or had a monotypic DENV antibody response when they entered the trial. Assuming the probability of seroconversion for seronegative or monotypic individuals was 10% with a coefficient of variation of 0·25, and an alpha of 5%, we estimated we would need 26 clusters (13 per arm) with approximately 60 qualifying individuals to achieve a power of 80% to detect a reduction in the odds of 30%.

The primary endpoint was ABV seroconversion, as measured by DENV- or ZIKV-specific neutralizing antibodies, in blood from children $\geq$ 2 years to $\leq$ 18 years. To increase the pool of baseline seronegative participants, we expanded screening to

147 ≥18 years. Secondary endpoints were clinically apparent laboratory confirmed ABV
148 disease and indoor female *Ae.* aegypti: 1) abundance, 2) blood-fed status (proxy for
149 human-biting rates), and 3) parity status (proxy for age-structure). Participants
150 followed for seroconversion were the 'longitudinal cohort' and those followed for
151 disease were the 'febrile surveillance cohort'.
152

153 RANDOMIZATION AND INTERVENTION

154 A total of 26 clusters (13 per arm) each with approximately 140 households (60
155 qualifying participants) were randomly allocated in August 2016 to receive SR or
156 placebo intervention by the external statistician serving on the Data Safety Monitoring
157 Board (DSMB) using a random number generator (https://www.random.org) (SI
158 Section 1.2.1). Investigators, research staff, and study participants were blinded to
159 cluster allocation. Our intervention was a transfluthrin passive emanator designed
160 and produced by SC Johnson (Racine, WI), replaced at 2-week intervals, as
161 described previously (Figure S1, SI Section 1.3.2).[16] Spatial repellent and placebo
162 intervention had identical packaging and were deployed in houses by study personnel
163 using a blinded coding scheme. The placement of the intervention followed
164 manufacturer specifications for indoor use conditions.
165

166 SEROCONVERSION AND DISEASE SURVEILLANCE

167 Recruitment for the longitudinal cohort focused on children because they were likely
168 to be antibody test-negative or monotypic at baseline, which would facilitate
169 interpretation of laboratory assays, and less mobile than adults[17], thus spending more

170 time in their houses or their assigned cluster. Baseline blood samples were obtained
171 within 2 weeks before or after initial intervention deployment. As new families moved
172 into the study area, they were recruited to participate, resulting in longitudinal
173 participant enrollment throughout the interval between Baseline (B), First (F), and
174 Second/Final (S) longitudinal blood draws (Figure 3). Samples were tested by
175 microneutralization enzyme immunoassay (MNT) for seroconversion to each DENV
176 serotype and ZIKV (SI Sections 1.3.3.1 and 1.3.4.1). Only participants that provided
177 at least 2 blood samples were included in final analyses.
178
179 The febrile surveillance cohort was recruited by nurse technicians during door-to-door
180 wellness starting with the first week of intervention deployment. Suspected cases
181 exhibited axillary temperature of ≥ 37·5°C or, for suspected ZIKV infection, absence
182 of fever but presence of rash, arthralgia, arthritis, or non-purulent conjunctivitis for ≤
183 five days. Participants meeting these criteria provided acute and convalescent (14–21
184 days later) serum samples and were monitored clinically daily. Acute serum samples
185 were tested for viral RNA by PCR (DENV and ZIKV; SI Sections 1.3.3.2-1.3.3.4) and
186 by ELISA for DENV IgM (SI Sections 1.3.3.5,1.3.4.2).
187

188 ## ENTOMOLOGICAL ENDPOINTS

189 Indoor Prokopack aspirations[18] were conducted in all consented homes at time of first
190 intervention deployment and subsequent intervention replacement; i.e., two-week
191 intervals. Adult mosquitoes were transported to the NAMRU-6 Iquitos laboratory,
192 sedated at 4°C, identified to species and sex, counted by date and house. Up to 30

193 female *Ae. aegypti* per household per collection were examined for blood meal status
194 and scored as unfed, blood-fed (fully engorged, half-engorged, or trace amounts), or
195 gravid[19]. Standard insecticide resistance assays were used to assess vector
196 susceptibility to transfluthrin one-year into the trial (SI Section 1.3.5.2).
197

198 SAFETY MONITORING

199 Adverse events (AEs) and serious adverse events (SAEs) were actively collected
200 throughout the trial during surveillance follow-up and entomological surveys (SI
201 Section 1.3.6). Reported AEs were investigated by study staff and appropriate care
202 was recommended by a study physician within 24 hours. Safety reporting to the
203 NAMRU-6 IRB was managed by UC Davis in accordance with the approved protocol.
204 Quarterly reports summarizing reported AEs and SAEs were reviewed by the DSMB
205 for trial safety assessment.
206

207 STATISTICAL ANALYSIS

208 Details of our analytical approach are provided in the statistical analysis plan (SAP)
209 and SI Section 1.5. All analyses were conducted by RCR using R 3.6.1 (R Core
210 Team)[20] and the lme4[21] and survival[22] packages. No correction for multiple testing
211 was performed for secondary endpoint analyses and, as such, in accordance with
212 CONSORT guidelines, we do not present p-values.
213

214 The primary analysis was an intent-to-treat (ITT) assessment of ABV seroconversion
215 for all qualifying participants per treatment assignment who were >2 years to <18

years of age. Due to the rolling nature of enrollment, we used a survival analysis with a proportional hazards model and exponential distribution assumption for the baseline hazard (i.e., constant baseline hazard through time) and a frailty component to account for correlation within clusters. If $h(t_{ij}\,|x_{ij})$ is the hazard rate of the jth individual in the ith cluster with covariate values x_{ij} then this individual's hazard rate of an arbovirus infection can be written as:

$$h(t_{ij}\,|\,x_{ij}\,) = h_0\,(t_{ij}\,) \cdot \exp(\beta^T x_{ij} + W_i)$$

where $W_i \sim N(0, \sigma_c^2)$ is the random effect of the ith cluster. Covariates included age, sex, and treatment status (SR or placebo). PE was estimated as $PE = \left(1 - \exp(\hat{\beta})\right) \times 100\%$, where $\hat{\beta}$ is the estimated regression coefficient for the intervention group and $\exp(\hat{\beta})$ is the estimated hazard ratio (HR) between SR and placebo. The null hypothesis of PE = 0% is equivalent to $\beta = 0$, which is tested by Wald's test $z = \beta/s$, where s is the estimated standard error of $\hat{\beta}$, at the 1-sided significance level of 5%.

A Poisson generalized linear regression was used to assess intervention impact on clinical disease, with an offset for the number of participant-days each participant spent in each cluster. No covariates were used and due to the small sample size, no random effects were incorporated.

238 Indoor adult female *Ae. aegypti* abundance, blood-fed rates, and parity were tested
239 through a difference-in-difference Poisson generalized linear mixed models.
240 Collections conducted in 2016 were defined as 'baseline' and collections conducted
241 in 2017 and 2018 were estimated as 'post-baseline'. Each analysis accounted for
242 month of year and year as fixed effects and contained a random effect by cluster.
243 Model formulation details are in SI Sections 1.5.4-1.5.6.
244
245 The primary analysis conducted differs from that in the original SAP (SI SAP).
246 Procedures called for yearly blood draws from children. To increase the number of
247 qualifying participants, an expansion of the age range to all ages $\geq$ 2yrs. The rolling
248 enrollment resulted in substantial variation in time intervals between blood draws.
249 Simple logistic regression, therefore, was inadequate. The decision to alter the
250 primary analysis was discussed and agreed upon by the study statistician and the
251 external DSMB statistician before outputs were unblinded to the DSMB statistician.
252

253 # Results

254 ## STUDY POPULATION

255 A total of 2,215 persons were enrolled in the longitudinal cohort. Of these, 1,578
256 qualifying participants were included in the ITT analysis for seroconversion (Figure 3)
257 representing a total of 196 ABV infections from 754 (1,090 paired samples) qualifying
258 participants in the SR arm and 294 ABV infections from 824 (1,237 paired samples)
259 qualifying participants in the placebo arm. Baseline covariates were balanced at both
260 the cluster and individual level (Table 1).

A total of 16,707 participants were followed for clinical disease, of which 16,683 were included in the ITT analysis (Figure S2). Baseline covariates for analysis of the secondary endpoint were balanced at both the cluster and individual level (Table S4).

INTERVENTION COVERAGE

The household participation rate (intervention deployed at some point during the study period) per cluster (SR and placebo) was of 56·6 % (SD = 10·5%), with slightly more participation in SR versus placebo clusters (58·8% v 54·5%, p-value = 0·336). In households consenting to receive intervention (SR or placebo), the mean percentage of days covered by an intervention at the cluster-level was 81·6% (SD = 3·9), with slightly higher coverage in households assigned to SR intervention (82·9%) compared to households in the placebo arm (80·3%), albeit insignificant (p-value = 0·153, Table S2, Figure S3). For all enrolled households, the mean percentage of days with an adequate intervention application rate (1 product per 9 m^2) was 73·6% (SD = 9·1), with similar rates between SR and placebo clusters (72·7% versus 74·5%, p-value > 0·999, Table S2).

SPATIAL REPELLENT EFFICACY

The estimated PE of SR intervention was 34·1% (1-sided 95% CI lower limit, 6·9%; (Table 2). Reduction in the arbovirus infection hazard rate was significant at the 5% significance level (Test statistic: z=1·98, 1-sided p-value = 0·02). Baseline covariates included in the statistical model on the hazard of arbovirus infection in qualifying

284 participants were age, which had statistically significant effects on the hazard of
285 arbovirus infection in qualifying participants, and sex, which did not. Hazard rate
286 increases by 4·6% for every one-year increase in age. Hazard rate decreases by
287 4·4% in males relative to females (Table 2). The originally proposed ITT mixed
288 effects logistic regression analysis, which ignores differential participation duration
289 across qualifying participants, produced a result consistent with those presented
290 here; i.e., PE > 30% and statistical significance at the 5% level (Table 2).
291
292 The Kaplan-Meier curves of arbovirus infection for qualifying participants by cluster
293 show considerable between-cluster variation (SR and placebo clusters) as evidenced
294 by the wide spread of survival curves (Figure 4). For example, there were no
295 arbovirus infections in qualifying participants in one placebo cluster; Cluster 7.2 had
296 only 18 qualifying participants. Conversely, in Cluster 8.2 almost half of the qualifying
297 participants with duration between serologic tests exceeded 15 months became
298 infected (5/11). The duration between tests varied by participant and across clusters
299 (Figure S4), resulting in some Kaplan-Meier curves being estimated beyond two
300 years. In many of those clusters, the only participants that went over two years
301 between blood sampling were universally found to have had an arboviral infection.
302
303 There were 96 disease cases detected, 51 in the SR arm and 45 in the placebo arm,
304 from 10,793,792 participant days that appeared balanced between SR and placebo
305 clusters (Table S4).
306

307 The estimated reduction adult female *Ae. aegypti* abundance in clusters receiving SR
308 intervention was 28·6% (1-sided 95% CI lower limit: 24·1%, test statistic: z= -9·11)
309 (Table 3). Baseline mosquito abundance was balanced between treatment arms
310 (Table S5) with post-baseline quantities estimated based on 47,518 and 43,417
311 household collections in SR and placebo arms, respectively. Baseline abundance
312 averaged 0·277 (standard deviation [SD] 0·153) and 0·279 (SD 0·122) per house
313 survey in SR and placebo arms, respectively, whereas post-baseline abundance
314 averaged 0·276 (SD 0·091) and 0·391 (SD 0·142) in the SR and placebo arms,
315 respectively (Table 3). There was a strong indication of seasonality, with z-scores
316 comparing each month to the reference month of January being at least 6 away from
317 0 (Table S7). Overall, abundance trended lower in the SR clusters compared to the
318 placebo clusters after intervention deployment from 2017-2019, the duration of the
319 trial (Figure 5).
320
321 The estimated reduction in the rate of blood-fed *Ae. aegypti* collected inside houses
322 was 12·4% (1-sided 95% CI lower limit: 4·2%, test statistic: z= -2·430) (Table 3).
323 Baseline abundance of engorged *Ae. aegypti* was balanced treatment arms (Table
324 S5) with post-baseline quantities estimated based on 9,257 and 11,496 mosquitoes
325 assessed for blood-fed status in SR and placebo arms, respectively. Baseline
326 abundance of blood-fed mosquitoes averaged 0·593 (standard deviation 0·440) and
327 0·536 (standard deviation 0·451) per collection in SR and placebo arms, respectively,
328 and post-baseline rates averaged 0·606 (SD 0·460) and 0·634 (SD 0·447) in SR and
329 placebo arms, respectively. There was no strong indication of seasonality (Table S8).

330

331 There was no observed intervention effect (Table 3) or indication of seasonality
332 (Table S9) based on the parity rate of *Ae. aegypti* females.

333

334 ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE).

335 There were 29 AEs reported during the trial (SI Section 2.8). Of these, three were
336 associated with blood draw (vasovagal response, two from SR and one from placebo
337 clusters) and 26 were consistent with transfluthrin (pyrethroid) exposure (22 from SR
338 and 4 from placebo clusters). Of the latter, the 26 affected individuals came from 18
339 households, often reporting different combinations of the following symptoms: allergic
340 response with itching and skin irritations (n=19; 15 from SR, four from placebo
341 clusters), dry mouth/bad taste (n=5, from SR clusters only), breathing issues (n=7,
342 from SR clusters only) including exacerbation of chronic bronchitis or asthma (n=2),
343 and headaches (n=4, from SR clusters only). No reported SAEs (deaths) were
344 deemed associated with the spatial repellent intervention.

345

346 Discussion

347 *Aedes*-borne viruses threats come from multiple viruses, which have expanding
348 regions of transmission and increasingly frequent epidemics. There is, therefore, a
349 growing unmet need for effective ABV disease prevention.[9] Our cRCT provides the
350 first conclusive evidence of significant PE against human ABV infection by any
351 chemical-based vector control intervention, in this case a spatial repellent.

352

353 PE was detected despite assumed dilution and contamination effects due to
354 participant movement in and out of study clusters. Unlike a vaccine, this intervention
355 protects the study participant in their own home or another protected home within
356 their neighborhood (i.e. Study Cluster), but does not provide continuous protection
357 once they leave treated houses. Our cohort, tested for ABV seroconversion, was
358 comprised principally of children ≤ 17 years of age, most who attended schools which
359 have been shown to be of lower risk of *Ae. aegypti* infestation than residential sites in
360 Iquitos.[23] Our outcome was demonstrated in an operational context, reflecting
361 complex interactions among ongoing Ministry of Health interventions across the study
362 area, imperfect coverage at the household-level (rooms closed to intervention,
363 homeowner removal and/or loss of intervention), <100% household participation
364 within clusters, and suggestion of pyrethroid resistance in the local *Ae. aegypti*
365 population.[24(**SI section 2.7**)] Reduced risk of ABV infection was associated with a
366 significant reduction in indoor female *Ae. aegypti* abundance and blood feeding.
367 Although entomological outcomes were modest, these effects are consistent with the
368 expected mode of action of SRs; i.e., deterrence from house entry and/or interfering
369 with human-biting.[12,25] Our entomological data will help guide indicators for next-
370 generation product development.
371
372 Our results support SRs as a flexible class of vector control products with positive
373 public health impact not limited to ABV diseases. Transfluthrin-[15] and metofluthrin-
374 based[16,26] mosquito coils have been shown to reduce malaria and the same spatial
375 repellent device used in our Iquitos trial reduced malaria infections in an Indonesia

376 cRCT.[15] Together, these results highlight the potential for SRs to reduce a variety of
377 vector-borne diseases, augment existing public health efforts and be an effective
378 component of vector control intervention strategies. To help guide implementation
379 and programmatic scale-up, additional assessments, which have already begun, [27–30]
380 are needed.
381
382 Our Peru cRCT is one of two trials recommended by the WHO for assessing public
383 health value and developing global health policy for the SR intervention class.[31] Our
384 study was powered to detect a 30% reduction in ABV infection risk. During the trial
385 period, dengue prevalence was lower than previous years and a Zika epidemic
386 occurred in 2016.[32] This uncertainty is typical of ABV transmission, making powering
387 of cRCTs challenging and helps explain why, until now, ABV cRCTs with
388 epidemiological outcomes have been rare.[33] We used seroconversion as our primary
389 endpoint of PE to address this challenge. In our setting, powering a trial based on
390 clinically apparent ABV disease would not be logistically feasible.
391
392 Fully integrating vector control into ABV disease prevention programs will require
393 quantitative guidance based on quantitative measures of the impact from each
394 intervention component. Ministries of Health, local to national governments and non-
395 governmental organizations can use our trial results as an evidence-base for
396 informed application of SRs. Considering the growing ABV public health threat,
397 difficulties of developing vaccines against multiple viruses and past, poorly informed

398 vector control failures,[9] enhanced ABV disease prevention will benefit greatly from
399 interventions with proven public health value.
400

401 Data sharing

402 De-identified analytical datasets, including deidentified participant data, data
403 dictionaries and analytical codes, will be made available with publication upon
404 request to RCR at bcreiner@uw.edu. Open-access distribution of the data will fall
405 under the terms of the Creative Commons Attribution (CC-BY) License, which permits
406 unrestricted use, distribution, and reproduction in any medium, provided the original
407 author and source are credited.
408

409 Acknowledgements

410 We extend sincere appreciation to DSMB members: Dennis Shanks, Chris Drakeley,
411 and Neal Alexander for assurances on data integrity and safety assessments. We
412 thank the WHO Vector Control Advisory Group (VCAG) for their comments during
413 project assessments. We are grateful for the efforts of Marianne Kent, Program
414 Coordinator at the University of Notre Dame, for her administrative, and logistical
415 support of the program, as well as, Brett Fox of the University of Notre Dame Center
416 for Research Computing for assisting with central database development for data
417 verification. We thank Kristina Davis and Matthew Sisk of the University of Notre
418 Dame Center for Research Computing and Hesburgh Libraries, respectively, for their
419 assistance in graphic development. We acknowledge Audrey Lenhart of the Centers
420 for Disease Control and Prevention (CDC) in Atlanta, GA USA and J. Kevin Baird of

421 the Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia and Nuffield
422 Department of Medicine, Centre for Tropical Medicine, University of Oxford, Oxford,
423 United Kingdom for their role on the Scientific Advisory Committee.
424
425 We express our gratitude to the Bill and Melinda Gates Foundation for their long-term
426 generosity and support of spatial repellent product evaluation and development,
427 especially Kate Aultman, Dan Strickman, and Alan Magill. We are deeply grateful to
428 SC Johnson for providing integral industry and product expertise including the
429 independent funding of the development, manufacturing, delivery, and shipment of
430 the intervention (SR and placebo) used in the study. SC Johnson provided expertise
431 in ensuring intervention quality, storage, application and disposal assurances
432 throughout the trial.
433
434 We thank the residents of Iquitos for their support and participation in this study and
435 willingness to allow this study to be conducted in their community. We greatly
436 appreciate support of the Loreto Regional Health Department including Drs. Hugo
437 Rodriguez-Ferruci, Christian Carey, Carlos Alvarez, and Lic. Wilma Casanova Rojas,
438 who facilitated our work in Iquitos. We thank the NAMRU-6 Virology and Emerging
439 Infections Department (VEID) leadership who provided institutional support, IRB
440 guidance, and support supervising field staff. We appreciate the careful commentary
441 and advice provided by the NAMRU-6 IRB and Research Administration Program for
442 the duration of this study. We thank the NAMRU-6 VEID field who provided daily
443 support through the duration of the project and without whom the recruitment of acute

444 dengue cases would not have been possible. In particular, we thank Cecilia
445 Gonzales, Gloria Talledo, and Gabriela Vasquez de la Torre for their administrative
446 support of the project.

447

448 Author contributions

449 Data were gathered by the field team in Iquitos (ACM, WHE, HA, IB, CS, and ABK);
450 laboratory testing by CG, PB, and AH; insecticide resistance testing by GMV, KEV,
451 and CFM; and human use issues were managed by ACM, SAJ, and WRC. ML
452 developed a Zika virus PCR assay used in the study. CDA provided Ministry of
453 Health entomological information and coordinated activities with Iquitos field teams.
454 The NAMRU-6 supervisory team in Lima included MS, SAJ, WRC, EJA, and RHD.
455 CM provided data management and ZIKV MNT laboratory testing. Statistical analysis
456 was conducted by RCR. The first draft of the manuscript was written by ACM, RCR,
457 TWS, and NLA, with revision following comments from all the authors.

458

459 Copyright statement

460 SAJ, WRC, EJA and RDH are military service members and ACM, HA, CG, IB, CS,
461 GMV, KE, CF, AAH, and MES are employees of the U.S. Government. This work was
462 prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright
463 protection under this Title is not available for any work of the United States
464 Government”. Title 17 U.S.C. §101 defines a U.S. Government work as a work
465 prepared by a military service member or employee of the U.S. Government as part
466 of that person’s official duties.

Disclaimer

The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.

Financial disclosure statement

This study was funded by the Bill and Melinda Gates Foundation (BMGF) to the University of Notre Dame (Grant# OPP1081737). Further support was provided by the Defense Threat Reduction Agency (DTRA), Military Infectious Disease Research Program (MIDRP, S0520_15_LI and S0572_17_LI), and the U.S. National Institute of Allergy and Infectious Diseases (NIH/NIAID) award number P01 AI098670. SC Johnson used internal company financial resources for the development, manufacturing, delivery, and shipment of the intervention (SR and placebo) used in the study.

Competing interests

The authors have declared that no competing interests exist.

485 ## References

486 1 Murray CJL, Barber RM, Foreman KJ, *et al.* Global, regional, and national
487 disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life
488 expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological
489 transition. *Lancet* 2015; **386**: 2145–91.

490 2 Stanaway JD, Shepard DS, Undurraga EA, *et al.* The global burden of dengue: an
491 analysis from the Global Burden of Disease Study 2013. *Lancet Infect Dis* 2016; **16**:
492 712–23.

493 3 Bhatt S, Gething PW, Brady OJ, *et al.* The global distribution and burden of
494 dengue. *Nature* 2013; **496**: 504–7.

495 4 Parks W, Lloyd L. Planning social mobilizaiton and communication for dengue
496 fever prevention and control. Geneva: WHO, 2004.

497 5 Esu E, Lenhart A, Smith L, Horstick O. Effectiveness of peridomestic space
498 spraying with insecticide on dengue transmission; systematic review. *Trop Med Int*
499 *Health* 2010; **15**: 619–31.

500 6 Horstick O, Runge-Ranzinger S, Nathan MB, Kroeger A. Dengue vector-control
501 services: how do they work? A systematic literature review and country case studies.
502 *Trans R Soc Trop Med Hyg* 2010; **104**: 379–86.

503 7 Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in
504 Effectiveness or Evidence?: Systematic Review and Meta-analysis. *PLoS Negl Trop*
505 *Dis* 2016; **10**: e0004551.

506 8 Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges
507 and proposing solutions for control of the virus vector Aedes aegypti. *PLoS Med*
508 2008; **5**: e68.

509 9 Achee NL, Gould F, Perkins TA, *et al.* A critical assessment of vector control for
510 dengue prevention. *PLoS Negl Trop Dis* 2015; **9**: e0003655.

511 10 Andersson N, Nava-Aguilera E, Arostegui J, *et al.* Evidence based community
512 mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the
513 Green Way): cluster randomized controlled trial. *BMJ* 2015; **351**: h3267.

514 11 Utarini A, Indriani C, Ahmad RA, *et al.* Efficacy of Wolbachia-infected mosquito
515 deployments for the control of dengue. *N Engl J Med* 2021; **384**: 2177–86.

516 12 Achee NL, Bangs MJ, Farlow R, *et al.* Spatial repellents: from discovery and
517 development to evidence-based validation. *Malar J* 2012; **11**: 164.

518 13 World Health Organization. WHO pesticide evaluation scheme. World Health
519 Organization, 2013 http://www.who.int/iris/handle/10665/78142.

520 14 WHO | Vector Control Advisory Group. 2020; published online Oct 6.
521 https://www.who.int/vector-control/vcag/en (accessed Nov 26, 2020).

522 15 Hill N, Zhou H, Wang P, Guo X, Carneiro I, Moore SJ. A household randomized,
523 controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination
524 with long-lasting insecticidal nets on the incidence of Plasmodium falciparum and
525 Plasmodium vivax malaria in Western Yunnan Province, China. Malaria Journal.
526 2014; **13**: 208.

527 16 Syafruddin D, Asih PBS, Rozi IE, *et al.* Efficacy of a Spatial Repellent for Control
528 of Malaria in Indonesia: A Cluster-Randomized Controlled Trial. *Am J Trop Med Hyg*
529 2020; published online May 18. DOI:10.4269/ajtmh.19-0554.

530 17 Vazquez-Prokopec GM, Bisanzio D, Stoddard ST, *et al.* Using GPS technology to
531 quantify human mobility, dynamic contacts and infectious disease dynamics in a
532 resource-poor urban environment. *PLoS One* 2013; **8**: e58802.

533 18 Vazquez-Prokopec GM, Stoddard ST, Paz-Soldan V, *et al.* Usefulness of
534 commercially available GPS data-loggers for tracking human movement and
535 exposure to dengue virus. *Int J Health Geogr* 2009; **8**: 68.

536 19 Gunning CE, Okamoto K, Astete H, *et al.* Efficacy of Aedes aegypti control by
537 indoor Ultra Low Volume (ULV) insecticide spraying in Iquitos, Peru. *PLoS Negl Trop*
538 *Dis* 2018; **12**: e0006378.

539 20 R Core Team. R: A language and environment for statistical computing. R
540 Foundation for Statistical Computing. Vienna, Austria, 2019 http://www.R-project.org/.

541 21 Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models
542 using lme4. arXiv [stat.CO]. 2014; published online June 23.
543 http://arxiv.org/abs/1406.5823.

544 22 Therneau TM. A Package for Survival Analysis in S. version 2.38. 2015; published
545 online Sept 28. http://cran.r-project.org/package=survival (accessed Jan 19, 2021).

546 23 Morrison AC, Sihuincha M, Stancil JD, *et al.* Aedes aegypti (Diptera: Culicidae)
547 production from non-residential sites in the Amazonian city of Iquitos, Peru. *Ann Trop*
548 *Med Parasitol* 2006; **100 Suppl 1**: S73–86.

549 24 Palomino-Salcedo M. [Estado de susceptibilidad de la población natural de Aedes
550 aegypti a los insecticidas en Punchana-Iquitos, Región Loreto (Novimbre 2014).
551 Instituto Nacional de Salud, Peru, 2014.

552 25 Norris E, Coats J. Current and future repellent technologies: The potential of
553 spatial repellents and their place in mosquito-borne disease control. *Int J Environ Res*
554 *Public Health* 2017; **14**: 124.

555 26 Syafruddin D, Bangs MJ, Sidik D, *et al.* Impact of a spatial repellent on malaria
556 incidence in two villages in Sumba, Indonesia. *Am J Trop Med Hyg* 2014; **91**: 1079–
557 87.

558 27 Liverani M, Charlwood JD, Lawford H, Yeung S. Field assessment of a novel
559 spatial repellent for malaria control: a feasibility and acceptability study in Mondulkiri,
560 Cambodia. *Malar J* 2017; **16**: 412.

561 28 Masalu JP, Finda M, Okumu FO, *et al.* Efficacy and user acceptability of
562 transfluthrin-treated sisal and hessian decorations for protecting against mosquito
563 bites in outdoor bars. *Parasit Vectors* 2017; **10**: 197.

564 29 Paz-Soldan VA, Plasai V, Morrison AC, *et al.* Initial assessment of the
565 acceptability of a Push-Pull Aedes aegypti control strategy in Iquitos, Peru and
566 Kanchanaburi, Thailand. *Am J Trop Med Hyg* 2011; **84**: 208–17.

567 30 Jumbam DT, Stevenson JC, Matoba J, *et al.* Knowledge, attitudes and practices
568 assessment of malaria interventions in rural Zambia. *BMC Public Health* 2020; **20**:
569 216.

570 31 World Health Organization. The evaluation process for vector control products.
571 World Health Organization, 2017 https://apps.who.int/iris/handle/10665/255644
572 (accessed Dec 2, 2020).

573 32 https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-situation-report-
574 per.pdf (Accessed Dec 2, 2020).

575 33 Anders KL, Cutcher Z, Kleinschmidt I, *et al.* Cluster-Randomized Test-Negative
576 Design Trials: A Novel and Efficient Method to Assess the Efficacy of Community-
577 Level Dengue Interventions. *Am J Epidemiol* 2018; **187**: 2021–8.

Figure 1. Location of 26 study clusters in Iquitos and Punchana Districts, Loreto Department, Iquitos, Peru. Each cluster consisted of ca. 140 households with an average distance of 300m between clusters.



583 **Figure 2.** Study timeline. Top panel: Human blood-sampling, disease surveillance,
584 and entomological monitoring in relation to deployment of the spatial repellent
585 intervention. Bottom panel: Intervention roll-out between August-December 2016 by
586 cluster. Horizontal numbers correspond to cluster numbers shown in Figure 1.



587

588

589

Figure 3. Allocation and follow-up of the longitudinal cohort population during three blood collection periods (Baseline [B], First [F] and Second/Final [S]). The majority (62%) of participants provided samples at each collection period, whereas some only participated during year 1 (B-F) or year 2 (F-S). Participants with a single sample were lost to follow-up and four individuals moved or had two houses located in the spatial repellent and placebo clusters are shown as removed at the baseline period for clarity.



Figure 4. Kaplan-Meier curves of arbovirus infection for 13 spatial repellent (SR) and 13 placebo clusters in qualifying participants measured by seroconversion (primary endpoint) by cluster.



604 **Figure 5.** Mean densities of adult female *Aedes aegypti* collected per household survey in 13 spatial repellent (SR) and
605 13 placebo clusters by study month. Shaded areas represent the 95% Confidence Interval around the mean.



606

607

608 **Table 1.** Summary of baseline characteristics, for qualifying participants of the intent-to-treat (ITT) longitudinal cohort
609 population in spatial repellent (SR) and placebo arms. Qualifying participants were defined as individuals in a participating
610 house who were seronegative or had a monotypic DENV antibody response when they entered the trial.

Individual-Level		
Variable	SR (n=898)	Placebo (n=952)
Age in years (mean±sd) (min, max)	10·88±4·62 (2, 47)	10·19±4·39 (2, 22)
Sex (% male)	51·6%	55·0%
Duration in years between samples (mean±sd) (min, max)	1·15±0·42 (0·02 ,2·29)	1·16±0·43 (0·01, 2·35)
No. qualifying participant observations	1,090	1,237
No. of arbovirus seroconversions	196	294
Cluster-Level		
Variable	SR (n=13)	Placebo (n=13)
Cluster population (mean±sd) (min, max)	58·2±30·4 (21,124)	73·5±35·3 (12,132)
Baseline susceptibility (mean±sd) (min, max)	81·0%±12·8% (54·7%,98·1%)	84·9%±6·3% (73·3%,92·5%)

611

612 **Table 2.** Protective efficacy (PE) estimates from intent to treat (ITT) analyses for the spatial repellent intervention against
613 *Aedes*-borne virus infection in qualifying participants measured by seroconversion (primary endpoint), including covariate
614 effects.

ITT analysis	**Hazard rate ratio (95% CI)**	**PE (%) (95% CI)**	**One-sided p-value**	**Covariate**	**Odds ratio (95% CI)**	**Two-sided p-value**
Survival analysis	0·659 (−∞,0·931)	34·1 (6·9,∞)	0·024			
				Age	1·046 (1·029-1·063)	$6·8 \times 10^{-6}$
				Male	0·956 (0·821-1·112)	0·62
ITT analysis	**Odds ratio (95% CI)**	**PE (%) (95% CI)**	**One-sided p-value**	**Covariate**	**Odds ratio (95% CI)**	**Two-sided p-value**
Odds reduction	0·547 (−∞,0·883)	45·3 (11·7,∞)	0·019			
				Age	1·071 (1·042-1·100)	$6·9 \times 10^{-7}$
				Male	0·950 (0·767-1·177)	0·64
Odds reduction on including 9–15-month sampling intervals	0·577 (−∞,0·879)	42·3 (12·1,∞)	0·016			
				Age	1·065 (1·028-1·103)	0·0005
				Male	0·970 (0·767-1·299)	0·779

615

616 **Table 3.** Rate reduction summary of indoor adult female *Aedes aegypti* abundance, blood-fed female abundance, and
617 parity rates (secondary endpoints) for primary (ITT) and secondary analyses (PP). No correction for multiple testing was
618 performed for secondary endpoint analyses and, as such, in accordance with CONSORT guidelines p-values are not
619 presented.

Indicator	Statistics	2016 Baseline[1]		Cluster-specific Baseline[2]	
		ITT	PP	ITT	PP
Indoor adult female *Aedes aegypti* abundance	Rate ratio (95% one-sided CI)	0·714 (−∞,0·759)	0·737 (−∞,0·784)	0·599 (−∞,0·633)	0·607 (−∞,0·641)
	Rate reduction (%) (95% one-sided CI)	28·6 (24·1,∞)	26·3 (16·2,∞)	40·1 (36·7,∞)	39·3 (35·9,∞)
Blood-fed female *Aedes aegypti* abundance	Rate ratio (95% one-sided CI)	0·876 (−∞,0·958)	0·876 (−∞,0·958)	0·908 (−∞,0·985)	0·929 (−∞,1·06)
	Rate reduction (%) (95% one-sided CI)	12·4 (4·2,∞)	12·4 (4·2,∞)	9·20 (1·49,∞)	7·10 (-6,∞)
Aedes aegypti parity rate	Rate ratio (95% one-sided CI)	0·922 (−∞,1·057)	0·921 (−∞,1·056)	0·928 (−∞,1·058)	0·909 (−∞,0·986)
	Rate reduction (%) (95% one-sided CI)	7·75 (-5·70,∞)	7·87 (-5·60,∞)	7·24 (-5·80,∞)	9·10 (-1·2,∞)

620 [1] Intent to treat (ITT, primary analysis) and per protocol (PP, secondary analysis) mixed effects difference-in-difference
621 (DID) Poisson regression specifying measurements made throughout 2016 as 'baseline', with post-2016 measurements
622 as 'post-baseline.' PP analysis only considering houses with SR application rates meeting manufactures specifications
623 ≥75% of the days between sequential blood sampling (designated PP-1).

624 [2] ITT and PP mixed effects DID Poisson regression specifying measurements made in 2016 up to the first date of
625 intervention deployed in each cluster as 'baseline' with all measurements following that date as 'post-baseline' for that
626 cluster, even for houses that did not enroll until 2017 or later. PP analysis only considering houses with SR application
627 rates meeting manufactures specifications ≥75% of the days between sequential blood sampling (designated PP-1).